Clinical Guest Contributors

  1. How Visible Is Your Clinical Trial To AI? 8/3/2026

    Ross Jacksons explores how clinical trials show up — it at all — in AI tools and what that means for sponsors' approach to publicizing trial information.

  2. Threat From Within: Why Biopharma's Drug Development Bottleneck Is Systemic 7/30/2026

    As FDA timelines and AI-enabled development accelerate, biopharma’s biggest bottleneck may be its own ability to make earlier, cross-functional decisions.

  3. Beyond Task Tracking: Why ClinOps Needs Dependency Intelligence 7/29/2026

    Clinical trial operations will always need task tracking, but they're not enough on their own. Dependency intelligence shifts the focus toward readiness not reaction.

  4. To Take On Transverse Myelitis, Researchers Must First Address Heterogeneity And Misguided Outcome Measures 7/29/2026

    UNC researcher Irena Dujmovic Basuroski, MD, Ph.D., discusses why transverse myelitis remains difficult to study, how multicenter collaboration and adaptive trial designs may help, and why better clinical, patient-reported, and biomarker-based measures are essential to advancing treatment.

  5. From Signal To Strategy: What Oncology Basket Trials Can Teach Clinical Development Teams 7/29/2026

    AbbVie's Svetlana Kobina discusses how basket trials can help clinical development teams move from early clinical signals to a more disciplined strategy.

  6. 4 Hidden Gaps In Clinical Trial Preparation For Small Biotechs 7/28/2026

    Gaps are not always visible at the executive level, but their consequences are very real — affecting timelines, budgets, data quality, and ultimately the likelihood of regulatory success.

  7. ImvivaBio's Trial For Off-The-Shelf CAR-T Strategy For Aggressive Malignancies 7/28/2026

    ImvivaBio CMO Jan Davidson-Moncada, MD, Ph.D., discusses the company's Phase 1b/2 study for aggressive T-cell malignancies, explaining their unmet need, the rationale for an allogeneic approach, and how they plan to address immune rejection.

  8. Clinical Trial Per-Patient Cost Analytics For Procurement And Sponsor Strategy 7/27/2026

    With the help of Beroe Inc.'s Surya Ponnam, discover how per-patient cost (PPC) analytics is evolving into a core capability for balancing cost, quality, speed, and patient outcomes.

  9. Expanded Access And Rollover Design Help CytoDyn Reach High-Need Cancer Patients 7/24/2026

    CEO Jay Lalezari and CFO Robert E. Hoffman share how CytoDyn meet patient needs when they approach trial design for cancer trials.

  10. Why Protocol Complexity Is Slowing First Patient In — And How Small Sponsors Can Fix Start-Up Inefficiencies 7/23/2026

    Protocol complexity directly affects timelines, costs, and execution quality. Consultant Jessica Cordes explains why this challenge requires sponsors to change their approach to protocol design, feasibility, and start-up.